Amortization of the deferred revenue - related party.

No definition available.

Name:	mgtx_AmortizationOfContractWithCustomerLiability
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaboration agreement upfront payment.

+ References

No definition available.

+ Details

Name:	mgtx_CollaborationAgreementUpfrontPayment
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Deferred revenue recognition estimated service period.

+ References

No definition available.

+ Details

Name:	mgtx_DeferredRevenueRecognitionEstimatedServicePeriod
Namespace Prefix:	mgtx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Deferred revenues amortization period.

+ References

No definition available.

+ Details

Name:	mgtx_DeferredRevenuesAmortizationPeriod
Namespace Prefix:	mgtx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of the clinical and commercialization costs of the products candidates to be paid by related party.

+ References

No definition available.

+ Details

Name:	mgtx_PercentOfClinicalAndCommercializationCostsPayableByRelatedParty
Namespace Prefix:	mgtx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of reimbursement of research and development expenses from related party.

+ References

No definition available.

+ Details

Name:	mgtx_RelatedPartyReimbursementOfResearchAndDevelopmentExpenses
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of royalties receivable on net sales of products and additional development and commercialization milestones.

+ References

No definition available.

+ Details

Name:	mgtx_RoyaltiesReceivable
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of royalties receivable on net sales of products and additional development and commercialization milestones, as a percent.

+ References

No definition available.

+ Details

Name:	mgtx_RoyaltiesReceivablePercentage
Namespace Prefix:	mgtx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_CommonStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=mgtx_ClinicalInheritedRetinalDiseaseProductCandidateDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_JohnsonAndJohnsonInnovationJjdcIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_JanssenPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=mgtx_ResearchDevelopmentAndCommercializationOfGeneTherapiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=mgtx_ResearchInheritedRetinalProductCandidatesDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=mgtx_RiboswitchResearchMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Related-Party Transactions - Collaboration and License Agreements (Details) - USD ($)			3 Months Ended		6 Months Ended		12 Months Ended
	Jan. 30, 2019	Oct. 16, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Feb. 27, 2019
Related Party Transaction [Line Items]
Shares issued to related party			37,362,416		37,362,416		36,791,906
Private Placement [Member]
Related Party Transaction [Line Items]
Shares issued to related party								5,797,102
Clinical IRD Product Candidate development \| Maximum [Member]
Related Party Transaction [Line Items]
Additional development and commercialization milestones	$ 340,000,000.0
Clinical IRD Product Candidate development \| Collaboration Agreement [Member]
Related Party Transaction [Line Items]
Royalties receivable, as a percentage	20.00%
JJDC \| Private Placement [Member]
Related Party Transaction [Line Items]
Shares issued to related party								2,898,550
Janssen Pharmaceuticals Inc [Member] \| Collaboration Agreement [Member]
Related Party Transaction [Line Items]
Non-refundable upfront fee received	$ 100,000,000					$ 100,000,000.0
Deferred revenue - related party recognized as license revenue			$ 2,473,705	$ 1,981,676	$ 6,683,281	2,766,636	$ 13,291,956
Reimbursement of research and development expenses			10,574,561	2,952,121	24,604,578	$ 3,989,663
Revenue, remaining performance obligation, amount			73,694,653		73,694,653
Estimated period to recognize remaining deferred revenue						4 years 9 months
Deferred revenue - related party			73,694,653		73,694,653		$ 86,214,091
Janssen Pharmaceuticals Inc [Member] \| Research, development and commercialization of gene therapies \| Collaboration Agreement [Member]
Related Party Transaction [Line Items]
Non-refundable upfront fee received	$ 100,000,000.0
Janssen Pharmaceuticals Inc [Member] \| Clinical IRD Product Candidate development \| Collaboration Agreement [Member]
Related Party Transaction [Line Items]
Percentage of clinical and commercialization costs to be paid by related party	100.00%
Janssen Pharmaceuticals Inc [Member] \| Research IRD Candidates development \| Collaboration Agreement [Member]
Related Party Transaction [Line Items]
Percentage of clinical and commercialization costs to be paid by related party	100.00%
Janssen Pharmaceuticals Inc [Member] \| Riboswitch Research \| Collaboration Agreement [Member]
Related Party Transaction [Line Items]
Deferred revenue - related party		$ 658,667
Deferred research funding, amortization period		8 months
Janssen Pharmaceuticals Inc [Member] \| Riboswitch Research \| Collaboration Agreement [Member] \| Research and Development Expenses [Member]
Related Party Transaction [Line Items]
Amortization of deferred revenue - related party			$ 0	$ 192,076	$ 0	$ 444,399